載入...
Initial Experience With Lung Cancer Resection Following Treatment With T Cell Checkpoint Inhibitor Therapy
T cell checkpoint inhibitors targeting the programmed death receptor-1 (PD-1) and its ligand (PDL-1) have recently been approved for the treatment of metastatic non-small cell lung cancer (NSCLC), but their safety and efficacy as neoadjuvant therapy are still undefined. Autoimmune toxicities, notabl...
Na minha lista:
| 發表在: | Ann Thorac Surg |
|---|---|
| Main Authors: | , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
2017
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5572805/ https://ncbi.nlm.nih.gov/pubmed/28838509 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.athoracsur.2017.03.038 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|